风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

NEJM：SOLIRIS（eculizumab）治疗神经脊髓炎视觉障碍的III期阳性数据

2019-05-05 不详 网络

神经脊髓炎视觉障碍Eculizumab补体
关注

Alexion制药公司近日宣布，新英格兰医学杂志（NEJM）公布了成人AQP4阳性神经脊髓炎视觉障碍（NMOSD）患者首次使用SOLIRIS®（eculizumab）（补体抑制剂）治疗的III期PREVENT研究的阳性数据。

Alexion制药公司近日宣布，新英格兰医学杂志（NEJM）公布了成人AQP4阳性神经脊髓炎视觉障碍（NMOSD）患者首次使用SOLIRIS®（eculizumab）（补体抑制剂）治疗的III期PREVENT研究的阳性数据。NMOSD是中枢神经系统（CNS）的罕见且破坏性的自身免疫性炎症疾病，其特征在于突然和不可预测的复发，且每次复发都会导致残疾的逐步累积，包括失明和瘫痪，有时甚至过早死亡。不受控制的补体激活是该疾病的主要潜在机制，目前没有针对NMOSD患者的批准疗法。

PREVENT研究表明，接受SOLIRIS的患者中有97.9％在48周时没有复发，而安慰剂组的这一数据为63.2％，且显著的复发减少持续了三年时间。同时，SOLIRIS的安全性与其他临床研究中的结果一致。


原始出处：

http://www.firstwordpharma.com/node/1638487?tsid=4#axzz5mwpWeWX8

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2020-03-07 12498484m54(暂无昵称)

    #视觉障碍#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2020-01-21 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-12-06 snowpeakxu

    #神经脊髓炎#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-09-05 zsyan

    #Eculizumab#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2020-03-27 xlysu

    #脊髓炎#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2020-04-18 bsmagic9132

    #Eculizuma#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-09-28 juliusluan78

    #III#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-05-07 zywlvao

    #视觉#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-05-07 智智灵药

    #III期#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1661283, encodeId=829b166128329, content=<a href='/topic/show?id=39c79088173' target=_blank style='color:#2F92EE;'>#视觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90881, encryptionId=39c79088173, topicName=视觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4c25257079, createdName=12498484m54(暂无昵称), createdTime=Sat Mar 07 16:53:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912130, encodeId=5ca619121309e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Jan 21 00:53:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949502, encodeId=05cb19495023b, content=<a href='/topic/show?id=f237e452185' target=_blank style='color:#2F92EE;'>#神经脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74521, encryptionId=f237e452185, topicName=神经脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Dec 06 08:53:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649635, encodeId=c35b16496351e, content=<a href='/topic/show?id=7cca651650' target=_blank style='color:#2F92EE;'>#Eculizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6516, encryptionId=7cca651650, topicName=Eculizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a24c23890249, createdName=zsyan, createdTime=Thu Sep 05 13:53:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650443, encodeId=454b165044359, content=<a href='/topic/show?id=b14384624a3' target=_blank style='color:#2F92EE;'>#脊髓炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84624, encryptionId=b14384624a3, topicName=脊髓炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06db24008155, createdName=xlysu, createdTime=Fri Mar 27 03:53:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934027, encodeId=1aaf193402eeb, content=<a href='/topic/show?id=a12465154c' target=_blank style='color:#2F92EE;'>#Eculizuma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6515, encryptionId=a12465154c, topicName=Eculizuma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Apr 18 03:53:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916099, encodeId=93f71916099f2, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Sep 28 13:53:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481120, encodeId=a5c81481120e4, content=<a href='/topic/show?id=c592908329c' target=_blank style='color:#2F92EE;'>#视觉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90832, encryptionId=c592908329c, topicName=视觉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adcf7732830, createdName=zywlvao, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594588, encodeId=b72e159458824, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 07 05:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034813, encodeId=28e01034813b6, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 05 17:53:00 CST 2019, time=2019-05-05, status=1, ipAttribution=)]
    2019-05-05 旺医

    顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息

    0

以上为热门评论，梅斯医学App还有更多内容